SavedAdd your journal

Journals / Ahi Evran Tıp Dergisi / 2026 / Volume: 10 Issue: 2

New-onset Ankylosing Spondylitis after COVID-19 mRNA Vaccine: A Case Report

COVID-19 mRNA Aşısından Sonra Yeni Başlangıçlı Ankilozan Spondilit: Bir Vaka Sunumu

Tuğba Özüdoğru Çelik(SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, ANKARA ŞEHİR SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ)0000-0003-0528-149X
Pages
—
Publication Date
2026-08-31
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this case, the aim is to present the diagnostic process of Ankylosing Spondylitis and the initiation of treatment of a 32-year-old young male patient whose complaints started after the Pfizer-BioNTech COVID-19 vaccine.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Autoimmune/autoinflammatory diseases, including rheumatic diseases, may occur and/or flare up after COVID-19 vaccines, due to the molecular similarities between viral antigens and antigenic structures in the human body.
📊
Key Findings & Data:Autoimmune/autoinflammatory diseases, including rheumatic diseases, may occur and/or flare up after COVID-19 vaccines, due to the molecular similarities between viral antigens and antigenic structures in the human body.
💡
Conclusion & Impact:In this case, the aim is to present the diagnostic process of Ankylosing Spondylitis and the initiation of treatment of a 32-year-old young male patient whose complaints started after the Pfizer-BioNTech COVID-19 vaccine.
🔬Design:Case Report
📍Scope:Comprehensive Sample
⚙️Variables:autoimmunity · inflammatory diseases · SARS-CoV-2 virus

Abstract

Autoimmune/autoinflammatory diseases, including rheumatic diseases, may occur and/or flare up after COVID-19 vaccines, due to the molecular similarities between viral antigens and antigenic structures in the human body. In this case, the aim is to present the diagnostic process of Ankylosing Spondylitis and the initiation of treatment of a 32-year-old young male patient whose complaints started after the Pfizer-BioNTech COVID-19 vaccine.

Özet

Virüs antijenleri ile insan vücudundaki antijenik yapılar arasındaki moleküler benzerlikler nedeniyle, romatizmal hastalıklar da dahil olmak üzere otoimmün/otoinflamatuar hastalıklar COVID-19 aşılarından sonra ortaya çıkabilir ve/veya alevlenebilir. Bu olgu sunumunda, Pfizer-BioNTech COVID-19 aşısından sonra şikayetleri başlayan 32 yaşında genç bir erkek hastada Ankilozan Spondilit tanı süreci ve tedavisinin başlatılması hakkında bir sunum yapılması amaçlanmıştır.

🔖

Cite This Article

Çelik, T. Ö. (2026). New-onset Ankylosing Spondylitis after COVID-19 mRNA Vaccine: A Case Report. Ahi Evran Tıp Dergisi, Volume: 10 Issue: 2. https://doi.org/10.46332/aemj.1757850

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Machado PM, Lawson-Tovey S, Strangfeld A, et al. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: Results from the EULAR Coronavirus vaccine (COVAX) physician-reported registry. Ann Rheum Dis. 2022;81(5):695-709. doi: 10.1136/annrheumdis-2021-221490.
  2. Dotan A, Muller S, Kanduc D, et al. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmune Rev. 2021;20(4):102792. doi: 10.1016/j.autrev.2021.102792.
  3. Liu Y, Sawalha AH, Lu Q. COVID-19 and autoimmune diseases. Curr Opin Rheumatol. 2021;33(2):155-62. doi: 10.1097/BOR.0000000000000776.
  4. Safary A, Esalatmanesh K, Eftekharsadat AT, Jafari Nakjavani MR, Khabbazi A. Autoimmune inflammatory rheumatic diseases post-COVID-19 vaccination. Int Immunopharmacol. 2022;110:109061. doi: 10.1016/j.intimp.2022.109061.
  5. Şenol Akar Ş, Taşbakan M. COVID-19 Aşılaması. Tosun S (ed). Sağlık Çalışanlarının Aşılanması. 1. Baskı. Ankara: Türkiye Klinikleri. 2022:50-55. ISBN: 978-625-401-641-7.
  6. Talotta R. Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to “potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases”. Clin Immunol. 2021;224:108665. doi: 10.1016/j.clim.2021.108665.
  7. Zhou Y, Han T, Chen J, et al. Clinical and autoimmune characteristics of severe and critical cases of COVID-19. Clin Transl Sci. 2020;13(6):1077-86. doi: 10.1111/cts.12805.
  8. Vlachoyiannopoulos PG, Magira E, Alexopoulos H, et al. Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19. Ann Rheum Dis. 2020;79(12):1661-3. doi: 10.1136/annrheumdis-2020-218009.
  9. Chen Y, Xu Z, Wang P, et al. New-onset autoimmune phenomena post-COVID-19 vaccination. Immunology. 2022;165(4):386-401. doi: 10.1111/imm.13443.
  10. Kocyigit BF, Akyol A. Reactive arthritis after COVID-19: A case-based review. Rheumatol Int.2021;41(11):2031-9. doi: 10.1007/s00296-021-04998-x.
  11. Türk SM, Öztürk Z, Karataş D, Gönüllü E. Inactıvated COVID-19 vaccıne can induce reactıve polyarthrıtıs in older patients: Report of two cases. Georgian Med News. 2021;(319):100-2. https://pubmed.ncbi.nlm.nih.gov/34749331/
  12. Theodorou DJ, Theodorou SJ, Axiotis A. COVID-19 vaccine-related myositis. QJM. 2021;114(6):424-5. doi: 10.1093/qjmed/hcab043.
  13. Wang J, Lou W, Li Y, Jiang Y, Jiang X, Yang L. Progress in targeted therapy for ankylosing spondylitis: A review. Medicine (Baltimore). 2024 Nov 29;103(48):e40742. doi: 10.1097/MD.0000000000040742.